510(K) CLEARANCES 84 ▲14RECALLS POSTED 39 ▲27CLASS I 6 ▲2PMA DECISIONS 47 ▲11WEEK ENDING / FDA DATA AS OF
Medical Device
ManufacturingTHE TRADE PAPER OF THE FACTORY FLOOR
SUBSCRIBE / SIGN IN
K101879Substantially Equivalent

Xpert Mrsa/sa Bc (Blood Culture) Assay Model Gxmrsa/sa-Bc-10

Cepheid, Sunnyvale CA / Special, Substantially Equivalent
FDA source (opens on fda.gov)510(k) summary (opens on fda.gov)

K101879 is the FDA 510(k) clearance record for XPERT MRSA/SA BC (BLOOD CULTURE) ASSAY MODEL GXMRSA/SA-BC-10, a class II device, cleared for Cepheid on under FDA product code NQX (System, Nucleic Acid Amplification Test, Dna, Methicillin Resistant Staphylococcus Aureus, Direct Specimen). FDA's definition for product code NQX reads: "A nucleic acid amplification assay system (including probes, other reagents, and instrumentation) is an aid in the identification of MRSA colonization status for the prevention and control of MRSA infections in healthcare settings". FDA records list 62 510(k) clearances for Cepheid, from to . As of , FDA records show one recall naming K101879.

Clearance record

Decision date
Received
(22 days to decision)
Product code
NQX System, Nucleic Acid Amplification Test, Dna, Methicillin Resistant Staphylococcus Aureus, Direct Specimen
Regulation
21 CFR 866.1640
Device class
Class II
Review panel
Microbiology
Applicant
Cepheid 904 Caribbean Dr., Sunnyvale CA
510(k) summary
Summary PDF
Third party review
No

Clearances, product code NQX

Trailing 12 months

FDA records hold no clearances under product code NQX in the trailing twelve months.

FDA records show no clearances under product code NQX in the twelve months to October 2026.
Show the numbers
Monthly 510(k) clearances under FDA product code NQX, trailing twelve months
MonthClearances
November 20250
December 20250
January 20260
February 20260
March 20260
April 20260
May 20260
June 20260
July 20260
August 20260
September 20260
October 20260